BioSpace News Archive

Data builds on Biogen’s core work in Alzheimer’s disease and movement disorders such as Parkinson’s disease and progressive supranuclear palsy; New aducanumab Phase 1b amyloid imaging analysis on the Centiloid scale; Biogen research programs target several of the identified causes of Alzheimer’s disease with an emphasis on early-stage disease

Collaboration advances commercial readiness for planned mid-2018 inotersen launch, positioning Akcea to successfully launch two drugs for significant rare diseases this year.

Oncorus®, Inc., a biotechnology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types, today announced that preclinical data on its oncolytic Herpes Simplex Virus (oHSV) immunotherapy platform will be presented at the American Association of Cancer Research (AACR) 2018 Annual Meeting to be held April 14-18, 2018 in Chicago, IL.

Massive Bio, Inc. announced that the first patient has been enrolled in a global registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool powered by a virtual tumor board (VTB) program.

X-Chem, Inc. announced the appointment of Christelle Huguet, Ph.D. as Chief Scientific Officer, along with an executive leadership appointment for Matthew Clark, Ph.D. as Senior Vice President, Chemistry.

Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases, today announced that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 28th Annual Healthcare Conference on Wednesday, March 21, 2018 at 3:55 PM ET in New York, NY.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results for fourth quarter and full year 2017.

Onxeo announced the presentation of two preclinical study abstracts highlighting AsiDNA™, the Company’s first-in-class DNA break repair inhibitor candidate, at the upcoming AACR Annual Meeting being held April 14-18, 2018 in Chicago, Illinois.

Nordic Nanovector ASA announces that it will present a poster reporting the anti-tumour effect of Humalutin® (177Lu-conjugated humanized anti-CD37 antibody, 177Lu-NNV003) in preclinical models of non-Hodgkin’s lymphoma at the AACR Annual Meeting 2018.

BerGenBio ASA announces that promising preclinical data with BerGenBio’s lead AXL inhibitor bemcentinib (formerly BGB324) will be featured at the 2018 American Association for Cancer Research (AACR) Annual Meeting on 14-18 April in Chicago, USA.